Slide 1

M.E.D.C. 2015 Sezione di Pneumologia ed Allergologia, U.O. Pediatria 1 Azienda Ospedaliero-Universitaria Pisana, Pisa

Slide 2

M.E.D.C. 2015 Get the right diagnosis Give an appropriate level of treatment Eliminate trigger factors from the environment Make sure the child and family know what it is all about and how to use the medication delivery device Bush A, Fleming L. Prim Care Respir J. 2012; 21: 242-4

Slide 3

M.E.D.C. 2015 Get the right diagnosis Give an appropriate level of treatment Eliminate trigger factors from the environment Make sure the child and family know what it is all about and how to use the medication delivery device Bush A, Fleming L. Prim Care Respir J. 2012; 21: 242-4 Give an appropriate level of treatment

Slide 4

M.E.D.C. 2015

Slide 5

2012 What is new in GINA 2014? 2014 Major Revision

Slide 6

Asthma is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation A new definition of asthma for clinical practice Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org

Slide 7

Reddel HK et al. Int J Tuberc Lung Dis. 2014; 18: 505-6 The 2014 GINA report covers all age groups, and includes a new chapter describing a syndromic approach to diagnosis of the asthma-COPD overlap syndrome (ACOS) M.E.D.C. 2015 Comprehensive and practical approach to asthma management (foundational role of ICS therapy, importance of non-pharmacological options) What is new in GINA 2014? Focus on common problems such as poor inhaler technique and adherence New sections on diagnosis and management for special populations, such as obesity and pregnancy

Slide 8

M.E.D.C. 2015 GINA 2012 GINA 2014

Slide 9

M.E.D.C. 2015 To achieve good control of symptoms and maintain normal activity levels To minimize future risk of exacerbations, fixed airflow limitation and side-effects Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org Long-term goals of asthma management in GINA 2014

Slide 10

Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org The control-based asthma management cycle M.E.D.C. 2015

Slide 11

Treatment options at a POPULATION level: e.g. national formularies, health maintenance organisations, national guidelines The preferred treatment at each step is based on: Efficacy Effectiveness Safety Availability and cost at the population level based on group mean data for symptoms, exacerbations and lung function (from RCTs, pragmatic studies and observational data) M.E.D.C. 2015 Population level vs Patient level decisions about asthma treatment

Slide 12

Decisions for individual PATIENTS Use shared decision-making wth the patient/parent/carer to discuss the following: 1.Preferred treatment for symptom control and for risk reduction 2.Patient characteristics (phenotype) Does the patient have any known predictors of risk or response? (e.g. smoker, history of exacerbations, blood eosinophilia) 3. Patient preference What are the patients goals and concerns for their asthma? 4. Practical issues Inhaler technique - can the patient use the device correctly after training? Adherence: how often is the patient likely to take the medication? Cost: can the patient afford the medication? M.E.D.C. 2015 Population level vs Patient level decisions about asthma treatment

Slide 13

CONTROLLED (All of the following) PARTLY CONTROLLED (Any measure in any week) UNCONTROLLED Daytime symptoms None (2 or less a week) > 2 a week Three or more features of partly controlled asthma present in any week Limitations of activities NoneAny Nocturnal symptoms NoneAny Need for reliever/rescue treatment None (2 or less a week) > 2 a week Lung function (PEF or FEV 1 ) Normal

How to start astma controller treatment Start controller treatment early For best outcomes, initiate controller treatment as early as possible after making the diagnosis of asthma Indications for regular low-dose ICS - any of: Asthma symptoms > 2 a month Waking due to asthma > 1 a month Any asthma symptoms plus any risk factors for exacerbations Consider starting at a higher step if: Troublesome asthma symptoms on most days Waking from asthma 1 a week, especially if any risk factors for exacerbations If initial asthma presentation is with an exacerbation: Give a short course of oral steroids and start regular controller treatment (e.g. high dose ICS or medium dose ICS/LABA, then step down) M.E.D.C. 2015 Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org

Slide 27

Remember to IMM AMBU Consider step down once good asthma control has been achieved and maintained for about 3 months, to find the patients lowest treatment that controls both symptoms and exacerbations M.E.D.C. 2015 Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org

Slide 28

Approach each step as a therapeutic trial. Engage the patient in the process; provide clear instructions, written asthma action plan, monitor symptoms and/or PEF; schedule a follow-up visit M.E.D.C. 2015 Choose an appropriate time (no respiratory infection, patient not travelling, not pregnant); close supervision Stepping down ICS doses by 25-50% at 3 month intervals is feasible and safe for most patients Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org How to step down asthma treatment? Consider step down once good asthma control has been achieved and maintained for about 3 months, to find the patients lowest treatment that controls both symptoms and exacerbations

Slide 29

Short-term step-up, for 1-2 weeks, e.g. with viral infection or allergen (may be initiated by patient with written asthma action plan) How to step up asthma treatment? M.E.D.C. 2015 Sustained step-up, for at least 2-3 months if asthma poorly controlled (Important: first check for common causes like symptoms not due to asthma, incorrect inhaler technique, poor adherence) Day-to-day adjustment (For patients prescribed low-dose ICS/formoterol maintenance and reliever regimen) Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org

Slide 30

How to distinguish between Uncontrolled and Severe asthma M.E.D.C. 2015

Slide 31

Low, medium and high dose ICS Children 6-11 years Inhaled corticosteroidTotal daily dose (mcg) LowMediumHigh Beclometasone dipropionate (HFA)50-100>100-200>200 Budesonide (DPI)100-200>200-400>400 Budesonide (nebules)250-500>500-1000>1000 Ciclesonide80>80-160>160 Fluticasone propionate (DPI )100-200>200-400>400 Fluticasone propionate (HFA)100-200>200-500>500 Mometasone furoate110220 800-1200>1200 M.E.D.C. 2015 Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org

Slide 32

Inhaled corticosteroidTotal daily dose (mcg) LowMediumHigh Beclometasone dipropionate (HFA)100-200>200-400>400 Budesonide (DPI)200-400>400-800>800 Ciclesonide (HFA)80-160>160-320>320 Fluticasone propionate (DPI or HFA)100-250>250-500>500 Mometasone furoate110-220>220-440>440 Triamcinolone acetonide400-1000>1000-2000>2000 M.E.D.C. 2015 Low, medium and high dose ICS Adults and adolescents (12 years) Adults and adolescents (12 years) Global Initiative for Asthma (GINA) Guidelines 2014 - www.ginasthma.org

Slide 33

M.E.D.C. 2015

Slide 34

2012 2014 What is new in BTS/SIGN GL 2014?

Slide 35

M.E.D.C. 2015

Slide 36

Slide 37

What is new in BTS/SIGN GL 2014?

Slide 38

M.E.D.C. 2015 What is new in BTS/SIGN GL 2014? Bronchial termoplasty may be considered for the treatment of adult patients who have poorly controlled asthma depite optimal therapy BTS / SIGN Asthma Guidelines 2014 - www.brit-thoracic.org.uk

Slide 39

M.E.D.C. 2015 What is new in BTS/SIGN GL 2014? BTS / SIGN Asthma Guidelines 2014 - www.brit-thoracic.org.uk Normal Airway Asthmatic Airway Asthmatic Airway during attack

Slide 40

In lung diseases exacerbations are not a temporary inconvenience, and can be associated with permanent damage and a worse prognosis which should call forth immediate action Full review of all aspects of the problem, including co-morbidities, management, adherence, environmental factors Bush A. Thorax. 2011; 66: 367 M.E.D.C. 2015 The term lung attack may resonate more with patients and the broader community

Slide 41

Effects of repeated bronchoconstriction Grainge CL, Lau LC, Ward JA et al. N Engl J Med. 2011; 364: 2006-15 This study shows that repeated bronchoconstriction in asthma promotes airway remodeling The changes were evident 4 days after repeated airway challenges and were independent of the stimulus causing the bronchoconstriction M.E.D.C. 2015

Slide 42

Steroid Phobia M.E.D.C. 2015

Slide 43

Zhang L, Prietsch SOM, Ducharme FM. Cochrane Database Sys Rev. 2014; 7: CD009471 Pruteanu AI, Chauhan BF, Zhang L. et al. Cochrane Database Sys Rev. 2014; 7: CD009878 Small but statistically significant group difference in growth velocity (0,2 cm/yr) between low doses of ICS and low to medium doses of HFA-beclomethasone equivalent, favouring the use of low-dose ICS Regular use of ICS at low or medium daily doses is associated with a mean reduction of 0.48 cm/y in linear growth velocity and a 0.61 cm change from baseline in height during a one- year treatment period

Slide 44

What about steroid-phobia? Asthma inhalers make children half a centimeter shorter - The Telegraph 2014, July the 17th Half a centimeter in growth is a a small price to pay for medicine which may save your childs life! M.E.D.C. 2015

Slide 45

XIX Congresso SIMRI - Torino 22-24/10/15

Slide 46

Slide 47

Slide 48

Global Initiative for Asthma Avoidance of tobacco smoke exposure Provide advice and resources at every visit; advise against exposure of children to environmental tobacco smoke (house, car) Physical activity Encouraged because of its general health benefits. Provide advice about exercise-induced bronchoconstriction Occupational asthma Ask patients with adult-onset asthma about work history. Remove sensitizers as soon as possible. Refer for expert advice, if available Avoid medications that may worsen asthma Always ask about asthma before prescribing NSAIDs or beta-blockers Breathing techniques (no specific technique) May be a useful supplement to asthma medications (Allergen avoidance) (Not recommended as a general strategy for asthma) See GINA Box 3-9 and online Appendix for details Non-pharmacological interventions GINA 2014, Box 3-9 This slide shows examples of interventions with high quality evidence

Slide 49

Presenting symptoms Preferred initial controller Asthma symptoms or need for SABA < 2 a month; no waking due to asthma in last month; and no risk factors for exacerbations including no exacerbations in the last year No controller Infrequent asthma symptoms, but the patient has one or more risk factors for exacerbations; e.g. low lung function, or exacerbation requiring OCS in the last year, or has ever been in intensive care for asthma Low dose ICS Asthma symptoms or need for SABA between 2 a month and 2 a week, or patient wakes due to asthma once or more a month Low dose ICS Asthma symptoms or need for SABA > 2 a week Low dose ICS Other less effective options: LTRA or Theophylline Recommended options for initial controller treatment in adults and adolescents M.E.D.C. 2015

Slide 50

Presenting symptoms Preferred initial controller Troublesome asthma symptoms most days; or waking due to asthma once a week or more, especially if any risk factors exist Medium/high dose ICS or Low dose ICS/LABA Initial asthma presentation is with severely uncontrolled asthma, or with an acute exacerbation Short course of oral corticosteroids AND Start regular controller treatment; options are High-dose ICS or Moderate-dose ICS/LABA Recommended options for initial controller treatment in adults and adolescents M.E.D.C. 2015

Slide 51

Global Initiative for Asthma Treating modifiable risk factors Provide skills and support for guided asthma self-management This comprises self-monitoring of symptoms and/or PEF, a written asthma action plan and regular medical review Prescribe medications or regimen that minimize exacerbations ICS-containing controller medications reduce risk of exacerbations For patients with 1 exacerbations in previous year, consider low-dose ICS/formoterol maintenance and reliever regimen* Encourage avoidance of tobacco smoke (active or ETS) Provide smoking cessation advice and resources at every visit For patients with severe asthma Refer to a specialist center, if available, for consideration of add-on medications and/or sputum-guided treatment For patients with confirmed food allergy: Appropriate food avoidance Ensure availability of injectable epinephrine for anaphylaxis M.E.D.C. 2015